Insider Buying: Talphera (NASDAQ:TLPH) CEO Purchases $125,852.90 in Stock

Talphera, Inc. (NASDAQ:TLPH) CEO Vincent Angotti bought 213,310 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was bought at an average price of $0.59 per share, with a total value of $125,852.90. Following the acquisition, the chief executive officer owned 800,705 shares in the company, valued at approximately $472,415.95. This trade represents a 36.31% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Talphera Stock Performance

NASDAQ:TLPH opened at $0.74 on Friday. The stock’s fifty day moving average is $0.87 and its 200 day moving average is $1.05. Talphera, Inc. has a fifty-two week low of $0.38 and a fifty-two week high of $1.57. The firm has a market capitalization of $37.11 million, a PE ratio of -2.00 and a beta of 0.47.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Equities analysts forecast that Talphera, Inc. will post -0.64 EPS for the current year.

Hedge Funds Weigh In On Talphera

Institutional investors have recently made changes to their positions in the company. AIGH Capital Management LLC raised its holdings in shares of Talphera by 4.6% in the fourth quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company’s stock valued at $5,314,000 after acquiring an additional 206,957 shares in the last quarter. Rosalind Advisors Inc. grew its holdings in Talphera by 118.9% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after acquiring an additional 2,381,818 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Talphera by 75.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after acquiring an additional 1,500,000 shares in the last quarter. Empery Asset Management LP purchased a new position in Talphera during the 4th quarter valued at about $1,520,000. Finally, Cantor Fitzgerald L. P. purchased a new position in Talphera during the 4th quarter valued at about $658,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.